Prostate-Specific Antigen: What's New in 1997

ONCOLOGY

Volumn 11, Issue 9, 1997, Pages 1273-1278

  Pannek, Jürgen ^a   Partin, Alan W ^b  

^a Department of Urology ^*  (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; RNA DIRECTED DNA POLYMERASE; TUMOR MARKER;

CHEMISTRY; HUMAN; MALE; METHODOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; REVIEW; SENSITIVITY AND SPECIFICITY;

HUMANS; KALLIKREINS; MALE; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA-DIRECTED DNA POLYMERASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031226508     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: Update 1994. J Urol 152:1358-1368, 1994.
2. Hara M, Inorre T, Fukuyama T: Some physico-chemical characteristics of gamma-seminoprotein, an antigeneic component specific for human seminal plasma Jpn J Legal Med 25:322-325, 1971.
3. Brawer MK, Lange PH: Prostate specific antigen: Its role in early detection, staging and monitoring of prostatic carcinoma. J Endourol 3:227-236, 1989
4. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747-752, 1990.
5. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 274 1214-1220, 1995.
6. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993.
7. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease JAMA 267:2215-2220, 1995.
8. Seaman E, Whang IS, Olsson CA, et al: PSA density (PSAD). Role in patient evaluation and management Urol Clin North Am 20:653-663, 1993
9. Oesterling JE, Jacobsen SJ, Chute GC, et al: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860, 1993.
10. 1- antichymotrypsin. Urol Clin North Am 20:681-686, 1993.
11. Arnheim N, Erlich H: Polymerase chain reaction strategy. Ann Rev Biochem 61:131-156, 1992.
12. st International Consultation on Prostate Cancer, 1997 (in press).
13. Parker SL, Tong T, Bolden S, et al: Cancer statistics 1996. CA Cancer J Clin 46:5-27, 1996.
14. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317:909-916, 1987.
15. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841-845, 1992.
16. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA 270:948-954, 1993.
17. Labrie F, Dupont A, Suburu R, et al: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147:846-852, 1992.
18. Cooner WH, Mosley BR, Rutherford, Jr CL, et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen J Urol 143:1146-1154, 1990.
19. Brawer MK, Beatie J, Wener MH, et al: Screening for prostate carcinoma with prostate-specific antigen: Results of the second year. J Urol 150:106-109, 1993.
20. Andriole GL, Catalona WJ: Using PSA to screen for prostate cancer: The Washington University experience. Urol Clin North Am 20:647, 1993.
21. Walsh PC: Using prostate-specific antigen to diagnose prostate cancer: Sailing in uncharted waters. Ann Intern Med 119:948-949, 1993.
22. Stamey TA, Kabalin JN, McNeal JN, et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol 141:1076-1083, 1989.
23. Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: A means of distinguishing bemgn prostatic hypertrophy and prostate cancer. J Urol 147:815-816, 1992.
24. Brawer MK, Aramburu EAG, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150:369-373, 1993.
25. Wolff JM, Boeckmann W, Effert PJ et al: Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Br J Urol 76:41-46, 1995.
26. Ohori M, Dunn JK, Scardino PT: Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 46:666-671, 1995.
27. Catalona WJ, Richie JP, de Kernion JB, et al: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2031-2036, 1994
28. Benson MC: Prostate specific antigen (editorial). J Urol 152:2046-2048, 1994.
29. Oesterling JE, Chute CO, Jacobsen SJ, et al: Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men. J Urol 149 412A, 1993.
30. Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152:1163-1167, 1994.
31. Carter HB, Pearson JD, Waclawiw Z, et al: Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 45:591-596, 1995.
32. Kadmon D, Weinberg AD, Williams RH, et al: Pitfalls in interpreting prostate specific antigen velocity J Urol 155:1655-1657, 1996.
33. Ruckle HC, Klee GG, Oesterling JE: Prostate-specific antigen: Critical issues for the practicing physician. Mayo Clin Proc 69:59-68, 1994.
34. Partin AW, Criley SR, Subong ENP, et al: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 155:1336-1339, 1996.
35. Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152:2037-2042, 1994.
36. Morgan TO, Jacobsen SJ, McCarthy WF, et al: Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 335:304-310, 1996.
37. DeAntoni EP, Crawford ED, Oesterling JE, et al: Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 48:234-239, 1996.
38. McCormack RT, Rittenhouse HG, Finlay JA, et al Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 45:729-744, 1995.
39. Huber PR, Mattarelli G, Strittmatter B, et al: In vivo and in vitro complex formation of prostate specific antigen with alpha-1-anti-chymotrypsin. Prostate 27:166-175, 1995.
40. Wang TJ, Hill T, Norton K, et al: Specific immunoassay for free PSA and its clinical relevance. J Urol 153(suppl):295A, 1995.
41. Semjonow A, Oberpenning F, Brandt B, et al: Impact of free prostate-spEcific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 48(6A):10-15, 1996.
42. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226, 1991.
43. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
44. Stenman UH, Alfthan H, Scandinavian BPH study group: Effect of long term treatment with finasteride on free and total PSA in serum. J Urol 155:698A, 1996.
45. Woodrum D, French C, Shamel LB: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 48(6A): 33-39, 1996.
46. Partin AW, Piantadorsi S, Subong ENP, et al: Clearance rate of serum -free and total PSA following radical retropubic prostatectomy. Prostate 7(suppl):35-39, 1996.
47. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percent free PSA for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 48(6A):55-61, 1996
48. Pannek J, Subong ENP, Jones KA, et al. The role of free/total prostate-specific antigen ratio in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology 48(6A):51-54, 1996
49. Arcangeli CG, Shepherd DL, Smith DS, et al: Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol 155:415A, 1996.
50. Saiki RK, Scharf S, Faloona F, et al: Enzymatic amplification of β-globin genomic sequences and restriction site analyses for diagnosis of sickle cell anemia. Science 230:1350-1354, 1985.
51. Katz AE, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43:765-775, 1994.
52. Ignatoff JM, Oelfelein MG, Herz B, et al: Prostate specific antigen (PSA) specific reverse transcriptase-polymerase chain reaction (RT-PCR) assay in preoperative staging in prostate cancer. J Urol 155:417A, 1996.
53. Katz AE, de Vries GM, Benson MC, et al: The role of the reverse-transcriptase polymerase chain reaction assay for prostate specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am 23:541-549, 1996.
54. Sokoloff M, Tso CL, Kaboo S, et al: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: A clinicopathological molecular analysis of 121 patients. J Urol 156:1560-1566, 1996.
55. Slawin K, O'Hara SM, Song W, et al: Comparison of results obtained using different RT- PCR-PSA assay methods on a single set of clinical specimens. J Urol 155:417A, 1996.
56. Edelstein RA, Zietman A, de las Morenas A, et al: Implications of prostatic micrometastases to the pelvic lymph nodes: First report of an archival tissue gene expression study. J Urol 155:550A, 1996.
57. Wood DP, Weinstein M, Humphreys S, et al: Prognostic significance of circulating prostate cells. J Urol 155:418A, 1996.
58. Young CYF, Seay T, Hogen K, et al: Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate 7(suppl):17-24, 1996.
59. Smith JR, Freije D, Carpten JD, et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374, 1996.